Biogen joins immunology wave with $1.15 billion acquisition; Off-label treatment for alcohol use disorder is linked to slower liver decline, study suggests

Taking stock of the drug industry, from the lab to the medicine chest

May 22, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Ruby Wallau for STAT STAT+ | Biogen joins immunology wave with $1.15 billion acquisition Human Immunology Biosciences is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy. By Allison DeAngelis Off-label treatment for alcohol use disorder is linked to slower liver decline, study suggests A new study suggests that gabapentin could provide greater benefit than FDA-approved drugs for patients with alcohol-associated liver disease. By Isabella Cueto When should we start making H5N1 vaccine, and who will make that decision? In short, it's complicated Deciding when to start producing bird flu vaccine at scale, in the quantities needed for the entire world, is no easy feat. By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser